Archive - January 2023
FDA Proposes Gay-Friendly Blood Donation Policy
Heart Disease Named No. 1 Killer In 2020, Not COVID-19
Lilly breaks new ground for BTK class with Jaypirca approval
EMA reviewing Novartis’ Adakveo after phase 3 miss
Mental Health Bill assent: A Landmark Intervention
Trial sets up earlier use of J&J’s Carvykti in myeloma
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease